Alongside GlaxoSmithKline, I’d buy this FTSE share to make a million

When it comes to searching for shares to make a million, I reckon the healthcare sector is a well-stocked hunting ground.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As part of a diversified portfolio, I reckon the FTSE 100 pharmaceutical giant GlaxoSmithKline (LSE: GSK) could be a share to help me make a million. But it isn’t the only share in the wider healthcare sector I’d buy today.

One of the greatest attractions to me is the way GSK keeps pumping out shareholder dividends. It’s true the directors haven’t raised the dividend for a few years, but they haven’t reduced or axed it either – even during the Covid-19 crisis.

Steady progress

Worries about the timing-out of patents are receding. The company is rebuilding earnings gradually. It’s also restructuring, and the business keeps generating plenty of cash to support shareholder dividend payments.

In one example of progress, the company announced at the end of July it’s in advanced discussions with Sanofi to supply up to 300m doses of Covid-19 vaccine. Those talks relate to a vaccine candidate using Sanofi’s recombinant protein-based technology combined with GSK’s pandemic adjuvant system. Both companies reckon they will make their Covid-19 vaccine affordable and available globally.

I think the news underlines how well-placed the company is in the healthcare environment. My guess is those dividends will keep on coming in the years ahead. And with the share price near 1,586p, the yield is running at about 5%. I’d collect the income and reinvest it to help compound my way to a million.

But I’d go for the growth on offer with the FTSE 250’s UDG Healthcare (LSE: UDG) too. The company has a more-than-30-year history of dividend payments and the curve has been generally up. So, from UDG, I’d expect a rising income and capital appreciation from a climbing share price. With a long-term holding period in mind, I reckon UDG can help me invest my way to a million from shares.

Global operations

UDG operates in the wider healthcare sector. Around 68% of operating profit comes from advisory, commercial and clinical services. And the company derives 32% from clinical trial management and contract packaging services. One way of looking at it is that UDG provides some of the ‘picks and shovels’ needed by the healthcare industry, rather than producing drugs and treatments.

Operations are global. Last year, the firm earned around 64% of revenue in North America. Some 19% came from the UK, and 17% from the rest of the world. Meanwhile, today’s trading update covers the three months to the end of June. And UDG is one of those companies that has managed to keep trading through the pandemic after taking precautions such as requiring many of its staff to work from home.

Previously, the directors suspended the interim dividend, but have today announced that it will be paid to shareholders. I reckon that’s a good sign and underlines the strength of trading as well as the financial robustness of the business.

With the shares at 746p, the forward-looking earnings multiple for the trading year to September 2021 is about 18.5 and the anticipated dividend yield is just below 2%. That’s not a bargain valuation. But I think UDG could shape up to be a steady grower in the years ahead and contribute to a diversified portfolio of shares aimed at making a million.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has recommended GlaxoSmithKline and UDG Healthcare. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »